JP2023531567A - 進行性前立腺がんを判定するためのバイオマーカー組合せ - Google Patents

進行性前立腺がんを判定するためのバイオマーカー組合せ Download PDF

Info

Publication number
JP2023531567A
JP2023531567A JP2023523315A JP2023523315A JP2023531567A JP 2023531567 A JP2023531567 A JP 2023531567A JP 2023523315 A JP2023523315 A JP 2023523315A JP 2023523315 A JP2023523315 A JP 2023523315A JP 2023531567 A JP2023531567 A JP 2023531567A
Authority
JP
Japan
Prior art keywords
test
cap
population
subjects
psa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023523315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531567A5 (cg-RX-API-DMAC7.html
Inventor
ダグラス・キャンベル
タオ・ホ・レ
ヤンリン・ル
ブラッドリー・ウォルシュ
Original Assignee
ミノミック・インターナショナル・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902212A external-priority patent/AU2020902212A0/en
Application filed by ミノミック・インターナショナル・リミテッド filed Critical ミノミック・インターナショナル・リミテッド
Publication of JP2023531567A publication Critical patent/JP2023531567A/ja
Publication of JP2023531567A5 publication Critical patent/JP2023531567A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Databases & Information Systems (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2023523315A 2020-06-30 2021-06-30 進行性前立腺がんを判定するためのバイオマーカー組合せ Pending JP2023531567A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902212A AU2020902212A0 (en) 2020-06-30 Biomarker combinations for determining aggressive prostate cancer
AU2020902212 2020-06-30
PCT/AU2021/050705 WO2022000041A1 (en) 2020-06-30 2021-06-30 Biomarker combinations for determining aggressive prostate cancer

Publications (2)

Publication Number Publication Date
JP2023531567A true JP2023531567A (ja) 2023-07-24
JP2023531567A5 JP2023531567A5 (cg-RX-API-DMAC7.html) 2024-07-08

Family

ID=79317588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523315A Pending JP2023531567A (ja) 2020-06-30 2021-06-30 進行性前立腺がんを判定するためのバイオマーカー組合せ

Country Status (6)

Country Link
US (1) US20230305009A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172629A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023531567A (cg-RX-API-DMAC7.html)
AU (1) AU2021298661A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188184A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022000041A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023366061A1 (en) * 2022-10-20 2025-05-29 Minomic International Ltd. Methods for detecting aggressive prostate cancer
CN121101470B (zh) * 2025-09-08 2026-05-12 简勇 一种癌症危险程度辨别方法和系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509169A (ja) * 2005-09-19 2009-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 前立腺癌のためのバイオマーカー
WO2019065527A1 (ja) * 2017-09-29 2019-04-04 株式会社Ｊ－オイルミルズ 前立腺癌の検出方法
WO2020069580A1 (en) * 2018-10-05 2020-04-09 Minomic International Ltd. Biomarker combinations for determining aggressive prostate cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3011988A1 (en) * 2016-01-22 2017-07-27 Otraces Inc. Systems and methods for improving disease diagnosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509169A (ja) * 2005-09-19 2009-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 前立腺癌のためのバイオマーカー
WO2019065527A1 (ja) * 2017-09-29 2019-04-04 株式会社Ｊ－オイルミルズ 前立腺癌の検出方法
WO2020069580A1 (en) * 2018-10-05 2020-04-09 Minomic International Ltd. Biomarker combinations for determining aggressive prostate cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JINHUI ZHANG ET AL.: ""Proteomic and transcriptomic profiling of Pten gene‐knockout mouse model of prostate cancer"", THE PROSTATE, vol. 80, no. 7, JPN6025034987, 12 March 2020 (2020-03-12), pages 588 - 605, ISSN: 0005672364 *
SHENG-YU KU ET AL.: ""Towards precision oncology in advanced prostate cancer"", NATURE REVIEWS UROLOGY, vol. 16, no. 11, JPN6026021551, 7 October 2019 (2019-10-07), pages 645 - 654, ISSN: 0005874660 *

Also Published As

Publication number Publication date
EP4172629A1 (en) 2023-05-03
US20230305009A1 (en) 2023-09-28
EP4172629A4 (en) 2024-07-10
CA3188184A1 (en) 2022-01-06
WO2022000041A1 (en) 2022-01-06
AU2021298661A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
CA2516795C (en) Circulating tumor cells (ctc's): early assessment of time to progression,_survival and response to therapy in metastatic cancer patients
CN113439212B (zh) 用于确定侵袭性前列腺癌的生物标志物组合
TWI698639B (zh) 前列腺抗原標準品及其用途
CN101852805B (zh) Angptl3作为卵巢癌的诊断标记物的用途
JP7547332B2 (ja) 膀胱癌の検出
CN116660537A (zh) 一种评估三阴乳腺癌复发和预后的生物标志物及其应用
US20230305009A1 (en) Biomarker combinations for determining aggressive prostate cancer
AU2016297676B2 (en) Biomarker combinations for prostate disease
US20190361027A1 (en) Methods for determining breast cancer risk
US11791043B2 (en) Methods of prognosing early stage breast lesions
JP2023531567A5 (cg-RX-API-DMAC7.html)
CN119630966A (zh) 用于对膀胱癌进行风险分层和管理的方法和系统
AU2023366061A1 (en) Methods for detecting aggressive prostate cancer
US20240345092A1 (en) Risk prediction model for prostate cancer
HK1250257B (en) Biomarker combinations for prostate disease
WO2025049926A1 (en) Methods of selecting treatment options for cancer
CN101738478A (zh) Mmp9作为卵巢癌的诊断标记物的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602